[1]
Lim SW, Jin JZ, Jin L, Jin J, Li C. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. The Korean journal of internal medicine. 2015 Nov:30(6):759-70. doi: 10.3904/kjim.2015.30.6.759. Epub 2015 Oct 30
[PubMed PMID: 26552451]
[2]
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes care. 2006 Dec:29(12):2638-43
[PubMed PMID: 17130197]
[3]
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes care. 2007 Apr:30(4):890-5
[PubMed PMID: 17277036]
[4]
DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS, Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care. 2009 Sep:32(9):1649-55. doi: 10.2337/dc08-1984. Epub 2009 May 28
[PubMed PMID: 19478198]
[5]
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, obesity & metabolism. 2007 Sep:9(5):733-45
[PubMed PMID: 17593236]
[6]
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical therapeutics. 2006 Oct:28(10):1556-68
[PubMed PMID: 17157112]
Level 1 (high-level) evidence
[7]
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, obesity & metabolism. 2007 Mar:9(2):166-74
[PubMed PMID: 17300592]
Level 1 (high-level) evidence
[8]
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Jun:50(6):1148-55
[PubMed PMID: 17387446]
[9]
Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug design, development and therapy. 2013:7():989-1001. doi: 10.2147/DDDT.S37647. Epub 2013 Sep 17
[PubMed PMID: 24068868]
[10]
Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes. P & T : a peer-reviewed journal for formulary management. 2010 Sep:35(9):509-13
[PubMed PMID: 20975810]
[11]
Gupta V, Kalra S. Choosing a gliptin. Indian journal of endocrinology and metabolism. 2011 Oct:15(4):298-308. doi: 10.4103/2230-8210.85583. Epub
[PubMed PMID: 22029001]
[12]
Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ (Clinical research ed.). 2016 May 3:353():i2231. doi: 10.1136/bmj.i2231. Epub 2016 May 3
[PubMed PMID: 27142267]
Level 1 (high-level) evidence
[13]
Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic advances in drug safety. 2014 Jun:5(3):138-46. doi: 10.1177/2042098614523031. Epub
[PubMed PMID: 25083269]
Level 3 (low-level) evidence
[14]
Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, Melchiorri D, Pani L, AIFA Anti-diabetics Monitoring Group. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2014 Dec:24(12):1346-53. doi: 10.1016/j.numecd.2014.07.014. Epub 2014 Oct 6
[PubMed PMID: 25300980]
[15]
Yamasaki S, Kadowaki M, Jiromaru T, Takase K, Iwasaki H. Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2019 Jun:10(3):1139-1143. doi: 10.1007/s13300-019-0609-3. Epub 2019 Mar 29
[PubMed PMID: 30927215]
Level 2 (mid-level) evidence
[16]
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine. 2015 Jul 16:373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8
[PubMed PMID: 26052984]
[17]
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019 Jan 1:321(1):69-79. doi: 10.1001/jama.2018.18269. Epub
[PubMed PMID: 30418475]
Level 1 (high-level) evidence
[18]
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine. 2013 Oct 3:369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2
[PubMed PMID: 23992602]
[19]
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013 Oct 3:369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2
[PubMed PMID: 23992601]
[20]
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics. 2010 Sep:49(9):573-88. doi: 10.2165/11532980-000000000-00000. Epub
[PubMed PMID: 20690781]